Topiroxostat , 98% , 577778-58-6

CAS NO.：577778-58-6

Empirical Formula: C13H8N6

Molecular Weight: 248.24

MDL number: MFCD28384402

EINECS: 1592732-453-0

PRODUCT Properties

• Boiling point: 594.7±60.0 °C(Predicted)
• Density: 1.45±0.1 g/cm3(Predicted)
• storage temp.: Store at -20°C
• solubility: DMSO : 23.5 mg/mL (94.67 mM; Need ultrasonic and warming)
• form: Powder
• pka: 7.47±0.10(Predicted)
• color: White to off-white
• InChI: InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
• InChIKey: UBVZQGOVTLIHLH-UHFFFAOYSA-N
• SMILES: C1(C#N)=NC=CC(C2NN=C(C3C=CN=CC=3)N=2)=C1

Description and Uses

Topiroxostat is an orally-administered, non-purine, selective xanthine oxidase (XO) inhibitor developed for the treatment of hyperuricemia specifically for patients with gout in Japan. The drug was discovered and developed by Fuji Yakuhin. In contrast to conventional XO inhibitors such as febuxostat, topiroxostat interacts with key amino acid residues of the solvent channel.

Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Approved for therapeutic use in Japan since 2013, topiroxostat is marketed under the name Topiloric and Uriadec and is orally administered twice daily.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P261-P305+P351+P338